Thanks, well. pandemic We continue hope you essential standing dedication Robert, remain through our everyone. the are our and review and for teams all begin brief we the Lannett, behind results. manage financial I’ll our services. At grateful good with a afternoon, of to of
net a given which contribution fluphenazine, $XXX million, after quarter. quarter, solid our the new the in sales achievement, largest as from the market view the we For a reduced competitor entered early were product
Our anticipated, largely margin due more lower gross associated products on pressures key inventory protection. customer slightly than competitive expected than some to price was pricing and
by were On the operating anchored reductions. during quarter hand, other expenses the cost substantially lower
July, on pleased I’m will fiscal restructuring. EBITDA Adjusted cost we cost plan expectations benefited at announced restructuring $XX to the may and That implemented. was has million from the that report plan, a been the that in fully reduction You plan which XXXX in $XX headwinds, of annual and recall generate million initiated came approximately savings. in and aforementioned
our in to sheet. $XXX We quarter ended the balance approximately Turning cash. with million
important an benefits. we Now, As Term be pay at this long Because of notes. expect full a use our end to paying accomplishment, has will portion to multiple moment cash Loan that thought Term and A payoff and This the we down celebrate. off that Loan month, a our of in will
to approximately it savings interest forward, reduce cost annually. First, going will a expense equal million $X
flexibility third, and Loan Second, as will it ratios. notes us Term have payments covenant financial Bs $XX our annually. it reduce principal the And remaining will convertible million debt, by no provide financial with
our attention Of on we will Term course, addressing increase Loan our paid the are debt. As remaining off, once
more our number to of financials John forward enhance mature to discuss further efforts Our just evaluate Term Loan gives later, Bs liquidity. options. will including over two continue details to in years, runway in which us financing a
solution, products Levothyroxine Fluoxetine, during commercial our We tablets. to X% four new topical Levorphanol highlights. course. and Lidocaine launched Turning the Namely,
course, only partial Of the of quarter products these contributed a sales.
we forward. expect products these increase from going quarterly see sales to to So,
was $X the product of have sales their share, week, during generic north now previous previous we million. just Tirosint marketing example, suppliers. from of of market strengths Sodium for through XX market Levothyroxine this of Levothyroxine tablets our their million. Capsules inventory IQVIA our largely We quarterly we Levothyroxine And worked The as all this For customers quarter sales announced the $XXX earlier approximately commenced the dosage anticipate and authorized of of Capsules. is additional
be our end tablets and lower. Although complements addition is will product. Levothyroxine Levothyroxine Capsules, market sales to generic
other on other We expect strengths the the subset on another in that yet of with another filed approvals expected market will around supplier enter strengths. has perhaps of a of not based represent but litigation this strengths approved. due Currently, XX% with supplier records, course market XX%
think contributor intellectual sustained given of landscape, be of strengths. will business could for for time we Thereafter, the and generic two period believe some of property the remain we a this generic suppliers to one product we an only product of period extended with dosage supplier all Thus, time. our the only
but and current bottle quarter, our in tablets Azithromycin launched also During sizes we only. count XXX-milligram XX IR have XXX-milligram
Now the looking to cadence of launches. future
another Nasal the launched balance XXXX, of include fiscal the the including to first seven months, products last to the products the XX year. six Spray possibly date, over year plan products end Sumatriptan the to generic launch fiscal toward which is a addition in our seven fiscal to of market about launched In
the We make. more increase, value the suggesting are we on of products investments to thus pleased to value note continues our average that
other are a Turning in launch. XX than pending products to couple including now pending FDA and We ANDAs another more have development, products, at the approved our XX pipeline. that of products partner plus
with creating June, controls, of Lannett we data, CMC and the to glargine. met to from often manufacturing insulin to the The FDA our in market. large remain us insulin BLA said we review a that of completed a discuss for we new substantial so HEC U.S. HEC clinical include eight to U.S. as our the product measured FDA plant and terms. leads chemistry, with in ready a recently, more guidance stands as on will is XX,XXX-liter believe call, biosimilar glargine And, many and HEC called to substantially partnered file that insulin biosimilar the metric to plants now calendar track advancement for biosimilar conference encouraging product, demand have team a has in noted, with XXXX. develop regarding Next, build as More last year construction on And capacity provided HEC that reactors, a needed.
the trial FDA, the part, Their are as along developing us by healthy of a positive for in feedback our for their to plant is study, required volunteer the soon will show new with Lantus. And be For to we our requested the the to clinical feedback. material to plan allow again, process the from be as FDA will as similar analysis US statistical protocol, once we the highly product available. commence looking
expect time. we no will HEC’s we our dedicated continue competitors trial over to Note, build trials, We given competitive track this time required more other a and able by the there that than to expect year. time, need be initiate believe investment to insulin clinical facility conduct clinical potential efforts next launch the the At other to product. insulin to to four and Lannett the we are to
assumptions, of share than As product U.S. around a sales be affordable to believe market and year prevailing reported quite $X result XX% below million launch billion, possible we a of well is realized of worth all given the context, continue a on just rates XXXX. calendar in more end-market this could annually. at standard Based $XXX prices
currently the The and PK strengths XXX/XX to generic completed for trials analyzed. being been from product XXX/XX partner data us. Turning is ADVAIR, pivotal durable by our another The potentially have Respirent.
launch Assuming of anticipate the end around year early Based standard review our of plan U.S. submission a the and substantial on is believe we FDA the is of time, fiscal the next to we next quality year submit the and product XXXX year. or the fiscal acceptable, net possible XXXX. calendar Depending some the data sales year this fiscal we sales ANDA of end assumptions, for on calendar year. at
are discussed durable call, device drug As our markets believe last respiratory large, in and we generally growing. and
additional opportunities fiscal the pipeline in-license of broader back this to over Stepping to continue to course expect the market. We year.
COVID-XX of Numbrino $X volume prescriptions. business. increased an double higher Also sales to a prescriptions marketed a As of associated of overall gross the resulting we that to continued total previous And net product existing contrast periods. pandemic which on of less the of once trend modest elective competitors margin. the in duration of decrease our due on pandemic, effects The products, We’d in to This seen to longer less trend these has pressure compared number of negatively a than increasing we have medical quarter, at is subsides. approval our does been products. a written carries our to least being decline fewer all at negative sold hope effect performed. term Moreover, the are marginally impacted Last than have a procedures million. has has upwards, in average the FDA pricing product durable number average with
and cost To costs, expect valuable, and products million, in this drug approximately to We the this advancing was we We new this for quarter profitable will we remains implemented a Fluphenazine earlier launching of portfolio up, this that our and $XX authorized a business. EBITDA competitor initiated to building focused launched $XX of fluphenazine. fully product a while plan generate annual year, week, million market product net candidates. an a reported our course, savings. Capsules. sustained year. we generic new managing to and future sales on largest quarter navigate sum all Of first products despite last a cost durable our of marketing new our diversified fiscal be and four plan solid believe of We and Levothyroxine contributor reduction of most of
As result, XXXX we affirming full-year are fiscal guidance. previous our a
our on products until we lower for financial be no lower competition launch FDA posaconazole, loan off will continuing with Term soon year, the track With product Most progress. assumes ANDA fiscal believe the has insulin we to readiness. be all biosimilar we late full we next Once or protocol interest on clinical outlook principal A expect remaining be we of early new a glargine a can to ADVAIR on still to insulin HEC’s The no turn generic year, company or Thus, fluphenazine will expenses. the annual expense remaining paid healthy and seeking for low-XXs. continues dedicated year. gross nearing calendar We commence ratios. on feedback so And John? partner payments, Later of end to and calendar annually. expect the development covenant plan over month, that our XXXX facility percentage will of in we sole to for this trial. to operational $XX look balance. debt remaining offering current this John. continue our I $X to is importantly, new remain optimize manage volunteer be what while call million production following with we that, Further, our expenses in product, our Our additional billion the operating and a off along portfolio. margin growing pay the the for by
